Trials / Completed
CompletedNCT02977117
The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis
The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects With End-Stage Renal Disease Treated With Haemodialysis - A Randomised Clinical Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Iain Bressendorff · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to examine the effect of increasing dialyse magnesium on serum calcification propensity in subjects with end-stage renal disease treated with haemodialysis.
Detailed description
Patients with end-stage renal disease (ESRD) have a 20-fold increased risk of cardiovascular mortality compared to the general population. Arterial stiffness, likely due to vascular calcification (VC), has been shown to predict cardiovascular mortality in ESRD. Serum calcification propensity (T50) is a novel biomarker, which is believed to reflect the propensity toward ectopic calcification (e.g. VC). Increasing serum magnesium (sMg) should increase T50, which might in turn reduce the formation of VC in patients with ESRD. A cheap and easy way of achieving this would be to increase the concentration of Mg in the dialysate (dMg) of patients with ESRD treated with haemodialysis (HD). The investigators wish to conduct a randomised controlled double-blind clinical trial to examine whether increasing dMg will improve T50 in subjects with ESRD treated with HD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Dialysate magnesium (1.0 mmol/L) | Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation. |
| OTHER | Dialysate magnesium (0.5 mmol/L) | Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial. |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2016-11-30
- Last updated
- 2018-06-06
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02977117. Inclusion in this directory is not an endorsement.